It is not yet explored whether isoform-selective Hsp90i, especially Hsp90β-i, can sensitize prostate cancer and breast cancer to immunotherapy, which is the central question for the current study to address. The gene discussed is HSP90AB1; the disease is Familial prostate cancer.